210P Lung cancer: 10-year survival

Background: 10-Year survival (10YS) after radical surgery for non-small cell lung cancer (LC) patients (LCP) (T1-4N0-2M0) was analyzed. Methods: We analyzed data of 768 LCP (age = 57.6 ± 8.3 years) radically operated (R0) in 1985–2021 (m 660, f 108; lobectomies 514, pneumonectomies 254, only surgery-S 618, adjuvant chemoimmunoradiotherapy-AT 150: CAV/gemzar + cisplatin thymalin/taktivin radiotherapy 45–50 Gy; T1 320, T2 255, T3 133, T4 60; N0 516, N1 131, N2 121, M0 768; squamous 417, adenocarcinoma 301, large 50; early LC 214, invasive 554. Variables selected 10YS study were 45 blood parameters, sex, age, TNMG, type, tumor size. Cox modeling, SEPATH, Monte Carlo, bootstrap, neural networks computing used to determine any significant dependence. Results: Overall life span (LS) 2244.9 1750.3 days and 5-year (5YS) reached 72.9%, – 64.3%, 20 years 43.1%. 502 lived more than 5 years, 145 10 years.199 died because (LS 562.7 374.5 days). AT significantly improved (52.4% vs. 27.7%) (P 0.000 by log-rank test) with N1-2. modeling displayed that depended on: phase transition (PT) early-invasive terms synergetics, PT N0—N12, ratio factors-CRF (ratio between cells- CC cells subpopulations), G1-3, histology, glucose, AT, circuit, prothrombin index, heparin tolerance, recalcification time, weight, color index 0.000–0.039). Neural bootstrap simulation revealed relationships (rank 1), thrombocytes/CC (2), N0—N12 (3), segmented neutrophils/CC, healthy cells/CC, lymphocytes/CC, erythrocytes/CC, stick eosinophils/CC, leucocytes/CC. Conclusions: procedures cancer; N0–N12; CRF; circuit; biochemical factors; hemostasis system; AT; characteristics; anthropometric data; type. Optimal diagnosis treatment strategies are: screening detection; availability experienced thoracic surgeons complexity procedures; aggressive en block adequate lymphadenectomy completeness; precise prediction; unfavorable prognosis. Legal entity responsible the study: Oleg Kshivets. Funding: Has not received funding. Disclosure: The author has declared no conflicts interest.